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Abstract 
Background: Extended cycle hormonal contraceptives (e.g. Seasonale, Seasonique) when introduced in 2003 were considered a very 
novel approach to contraception. The idea of manipulating the menstrual cycle so that women would experience just four 
menstruations a year was radical and was assumed to be responsible for the slow acceptance rate among the general public. 
Objective: This report analyzes two different aspects of the acceptance of this unique idea in the population. The first was the level of 
usage of extended cycle hormonal contraceptives in the general population, which was measured by a review of sales figures over 
time in the United States. The second was an examination of market diffusion as it relates to consumer perceptions regarding the 
characteristics of these products. 
Methods: To determine the degree of usage of extended cycle hormonal contraceptives the yearly sales, in terms of units sold, were 
compared with that of other leading methods of hormonal contraception. Along with the data, survey answers were obtained from 
65 women who volunteered to participate in the study. Participants were selected randomly to represent the target population to 
assess the level of awareness about the benefits, risks, and any other concerns regarding the use of extended cycle hormonal 
contraceptives. 
Results: The yearly sales data of units sold showed a definitive increase in the sales of extended cycle hormonal contraceptives since 
their release on the market.  The survey results showed an overwhelming awareness in the study population about the extended 
regimen. However, only about half of the women in the survey group were aware of its benefits. The main concern reported was the 
perceived significant side effect profile. 
Conclusion: Though awareness about the extended cycle hormonal contraception regimen was widespread, the survey population 
was not well informed about the advantages and the disadvantages regarding the degree of severity of side effects.  To address 
these knowledge deficits, these aspects should be the focus when distributing information about extended cycle hormonal 
contraceptive regimens. This may boost the use of a potentially advantageous contraceptive regimen by a population who would 
derive benefit from its usage. 
 
 
Introduction 
The 91 day hormonal contraceptive method, also known as 
extended cycle contraception, was a radical approach to the 
conventional 28 day hormonal contraception, which had 
been in use for over fifty years. The proponents of this 
regimen advocated that by reducing the number of 
menstruations per year it would be possible to improve the 
quality of life, productivity, and provide respite from common 
symptoms experienced during menstruation. 
 
Extended cycle hormonal contraception was first proposed by 
Barr Pharmaceuticals in association with The Eastern Virginia 
Medical School, and was approved by FDA for distribution in 
September 2003. The extended cycle hormonal contraceptive 
regimen allowed women the opportunity to take a daily oral  
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contraceptive tablet, which skipped the menstrual cycle for 
three months in a row.  The package contains three packs of 
28 active pills (compared to 21 active and 7 inactive pills in a 
28 day regimen) with seven days of placebo or low dose 
hormone at the end of the third cycle.  This course allows for 
the menses to occur only at the end of three months or four 
times a year. 
 
Although a daily oral contraceptive is not novel, the concept 
of purposefully skipping menses for three months at a time 
has not wildly caught on yet.  This paper attempts to analyze 
how well this new approach to contraception been accepted 
in the community and what future challenges may lie ahead. 
Before the analysis of the acceptance of this new approach, it 
is beneficial to understand how new concepts are typically 
accepted in a community.  One model is the theory of 
“Diffusion of Innovation,” which explains how, why, and at 
what rate new ideas diffuse throughout a culture. Everett 
Rogers titled his 1962 book after this theory and explained, 
“Diffusion is the process by which an innovation is 
communicated through certain channels over time among 
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the members of a social system” [1].  Rogers described the S-
curve of society’s adoption of technology by dividing people 
into three groups based on their ability to adopt a change.  
The ‘innovators’ lead, the ‘early adopters’ are next to accept 
an idea, followed then by the majority until society has fully 
accepted the idea [1].  
 
Acceptance itself follows the ‘Innovation Decision Process,’ 
which begins with Stage 1: Knowledge, Stage 2: Persuasion, 
Stage 3: Decision, Stage 4: Implementation, and Stage 5: 
Confirmation. These stages correlate to the evolution of a 
person gaining knowledge of the innovation, forming an 
opinion, and then leading to the acceptance and confirmation 
of the innovation [1].  
 
Similarly, Coleman, Katz and Menzel studied the diffusion 
process of ideas, but through the impact of societal influence. 
Medical Innovation demonstrated the influence of 
interpersonal relationships at certain stages of the decision-
making process. Their 1966 study illustrated both individual 
and social variables affecting the adoption of new ideas and 
the influences existing from social or professional ties to the 
adopters [2].  
 
Ratna, et al. tested the willingness of doctors to adopt a new 
drug based on differing levels of influence, modeled their 
study after that of Coleman, Katz and Menzel.  The first group 
studied was the Baseline Scenario, where only one innovator 
or one journal was influential in the decision. Another group 
was the Heavy Media Scenario, where influences involved 
several individuals and journals. Finally, the third group, the 
Integration Scenario, involved no outside influence. The 
results showed that those in the Heavy Media Scenario group 
adopted the new drug in the least amount of time as 
compared to that of Baseline or Integration Scenario, the 
slowest adopters [3].  Essentially, the more influence from 
others who have adopted the idea or media showing its 
efficacy, the more willing they were to adopt the use of the 
new drug themselves. 
 
Viewing this information in light of acceptance of the 
extended cycle hormonal contraception, it can be assumed 
that the society consists of women who would be willing to 
accept the new idea more rapidly when recommended by 
sufficient numbers of peers.  This represents a traditional 
scenario of diffusion of innovation, and also is comprised of 
women who would be willing to try a new idea when 
influenced by the media. When hormonal contraceptives 
were originally introduced in the early 1960s the acceptance 
was slow, as the primary methods of diffusion was personal 
recommendations.  However, today the growing media 
campaigns and public reliance on the internet as a reliable 
source of information has made the diffusion of ideas much 
faster. As a result, we would expect that overall the 
acceptance of this new regimen of hormonal contraception 
should be faster than that of the traditional 28 day 
contraception products. 
 
Contraceptive options now range from patches, intravaginal 
rings, depot injections, and birth control pills.  In general, 
hormonal birth control has not changed profoundly in the 
past five decades, with only the real innovations in dosing.  
Over the years, studies have shown that women require 
much lower doses than originally thought for contraception, 
and that dosing varies from woman to woman.  An example 
of multiple dosing strengths was the introduction of Yaz 
shortly after Yasmin.  Yaz contains the same active 
ingredients as Yasmin, but with a lower dose of ethinyl 
estradiol (drospirenone 3 mg/ ethinyl estradiol 20 mcg and 
drospirenone 3 mg/ ethinyl estradiol 30 mcg, respectively).   
 
Even with the lower doses, some females were experiencing 
hormone withdrawal symptoms during the week of their 
menses.  For such occurrences, there was the innovation of 
low dose hormones during the week of menses.  Doses were 
low enough to allow menses to occur, but they did not 
deprive the body of hormones completely.  An example, 
Seasonique (levonorgestrel 0.15 mg/ ethinyl estradiol 0.03 
mg/ and ethinyl estradiol 0.01 mg), allows for a small amount 
of ethinyl estradiol to be delivered during menstruation in 
order to prevent withdrawal symptoms such as headache.  
Another advantage is its extended cycle allowing women to 
only experience four periods a year, therefore they have less 
cramping, headaches, and fatigue.  The 91 day regimens are a 
middle ground between the monthly period of a 28 day 
regimen and an alternative form of contraception such as 
hormonal rings and depot injections.   
 
Methodology 
This paper attempts to analyze the primary question of the 
level of diffusion or acceptance of this new approach to 
hormonal contraception via two methods, sales data and 
survey results. To mark the diffusion of this innovation for 
extended cycle hormonal contraception, the sales of units of 
91 day regimens versus other leading birth control regimens 
currently on the market were interpreted.  Sales data of the 
six leading hormonal contraceptive methods were analyzed 
to determine if the extended cycle hormonal contraceptive 
regimen is something that the public has accepted as 
compared to the typical 28 day tablet regimen.  The products 
included 91 day tablet Seasonale and Seasonique regimens; 
28 day tablet regimens of Yasmin, Yaz, Loestrin 24 FE; and 
Nuvaring. The sales data that were used to compare the sales 
of the above mentioned formulations were obtained from 
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Wolters Kluwer Pharma Solutions, a leading firm in the 
pharmaceutical market research space. 
 
Secondly, to have a comprehensive view of hormonal 
contraceptive attitudes and opinions, surveys were 
administered to characterize the diffusion of this idea 
through various age groups and gain opinions on the concept 
of 91 day contraception for the female target audience.  
Women were anonymously, randomly surveyed with a ten-
question multiple choice "Oral Contraception" questionnaire.  
The survey was distributed by pharmacy interns at four 
pharmacies in the greater Philadelphia and suburban New 
Jersey areas.  These pharmacies represented very different 
demographics and diverse neighborhoods.  Approximately 
200 questionnaires were distributed to female customers at 
these selected pharmacies.  The 65 returned surveys resulted 
in a response rate of 32.5 percent.  The questions ranged 
from current use and type of hormonal contraception, a 
willingness to take a 91-day regimen, and the knowledge of 
side effects and benefits of both 28 day and 91 day hormonal 
contraception regimens.  Participants remained anonymous, 
revealing only their age, so that women would be more 
comfortable sharing their true beliefs and feelings.  The study 
was not reviewed by an IRB since the survey was anonymous 
and no personal, identifiable data were collected. The surveys 
returned produced an age range of 19 to 52 years.  It was 
considered whether to exclude those already beyond 
menopause; however, by allowing all females to partake, 
more views were encompassed regardless if respondents 
were candidates for oral contraception.  The majority of 
participants were in their 20s, and this was an acceptable 
representation of the population that would be most likely 
using oral contraceptives, as physicians may recommend 
alternative methods contraception for women older than 35 
years. 
 
Results 
Upon comparison of the trends of popular contraception 
products, it was found that Seasonale's popularity rose 
continuously the first three years it was on the market, but 
then leveled out in its third and fourth years after release. 
With the introduction of Seasonique in 2006, Seasonale's unit 
sales decreased as Seasonique's increased, rising to surpass 
both Seasonale and Nuvaring.  Seasonique’s units sold was 
half that of Nuvaring (in its 5
th
 year on the market), but 
surpassed it by three times by the end of the following year 
[6].  This data was consistent with the position of Seasonique 
acting as a middle ground for women, as to not change their 
method of contraception, but provide unique benefits.  The 
28 day hormonal contraceptive regimen still remains the 
most popular, but 91 day regimens are becoming more 
widely accepted as shown by sales data.  
In the survey, a total of 65 completed responses were 
returned. Of this population, 40% were currently not using 
any form of oral hormonal contraception.  Women in this 
group tended to be older, but ages ranged from 19 to 50+ 
(with 6 participants over the age 30).  The most common 
(70%) reasons for not using oral contraception was either 
experiencing past side effects or having one or more 
contraindications to using hormonal contraception like 
increased blood pressure, migraines, etc.  About 23% of those 
women were on another method of birth control (non-
hormonal) such as condoms, natural family planning, etc.  
Despite not being on any type of hormonal contraception, 
88% had heard about Seasonique and Seasonale, mostly via 
television advertisements.   
 
Conversely, those who had “never heard of it” were all from 
women over the age of 47, leading us to believe that current 
television advertising for extended cycle hormonal 
contraception is primarily targeted toward a younger 
audience.  Another interesting finding was that only one 
respondent out of this group showed a willingness to try an 
extended regimen oral contraceptive in the future.  The rest 
of that group was evenly split between being somewhat 
willing, not willing, or not having enough information to make 
that decision.    
 
Women who were currently using oral contraceptives ranged 
in age from 20 to 28 years of age.  This seemed to be a 
representative portion of the general population who may 
use hormonal contraception, as women younger may not be 
on any contraception, and older women may be thinking 
about having children.  The respondents who were currently 
taking hormonal birth control were overwhelmingly (87%) on 
28 day regimens (Figure 1).  Only one person surveyed was 
currently on a 91 day regimen, while three others had been 
on it, but had switched to another method with no reason 
given.  Interestingly, of that group who had never taken a 91 
day regimen, 53% were willing to try an extended cycle 
regimen in the future (Figure 2).  Most of the respondents in 
this group had heard of Seasonale or Seasonique, and less 
than 10% felt they needed more information before trying it 
in the future. 
 
Regardless whether participants were using hormonal 
contraception, the responses were similar in the concerns 
with using a 91 day regimen.  The occurrence of side effects 
(e.g. spotting, weight gain) was the primary concern, followed 
by the belief that it is unnatural to skip menstrual cycles, the 
fear of missing signs of pregnancy followed closely behind 
(Figure 3).  Only a little more than half of the respondents 
were aware of the benefits of an extended cycle regimen 
with the percentage being 54% among women using oral 
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contraception and 58% of those not on hormonal 
contraception (Figure 4).   
 
Discussion 
The survey results showed that though there is an overall 
awareness of the availability of extended cycle hormonal 
contraception regimens, but not as much awareness of its 
benefits.  Participants were more aware of the 
drawbacks/side effects of the extended regimen.  This has 
been the case with other innovative therapeutic modalities 
such as Lasik eye surgeries, which achieved much notoriety in 
the initial years for their possible complications rather than 
the advantages it provides. With improvement in technology 
and better outcomes of the surgery there was a drastic 
increase in their subsequent acceptance in the population. 
The same may be considered when analyzing an extended 
cycle hormonal contraceptive regimen, which currently faces 
much skepticism due to its perceived complications, such as 
breakthrough bleeding or the unnaturalness of skipping 
menses [8]. It would be advantageous if physicians and media 
could disseminate the many benefits provided by this 
extended regimen when counseling patients about these 
products, so that women would be more aware of all aspects 
of the 91 day regimen.    
 
In conclusion, changing the public’s views is a constantly 
evolving process that requires years and an eventual tipping 
point to diffuse throughout society.  Innovations such as Lasik 
eye surgery may be often slow to take off, but eventually 
infiltrate common ideology.  Traditional 28 day oral 
contraception has been widely used for many decades; 
however, new formulations and dosing schedules allow 
women fewer periods a year with an overall improvement in 
the quality of life.  Although initially slow to gain popularity, 
based on the surveys and sales data, 91 day oral 
contraceptive regimens have progressed steadily into the 
mainstream and may be on their way to becoming an 
accepted and widely used form of birth control.   
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Figure 1. Use of Oral Contraceptive Types by Respondents 
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Figure 2.  Respondent Willingness to Try Extended Cycle Contraceptives Opinions 
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Figure 3.  Respondent Awareness of Extended Cycle Regimen Benefits 
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Figure 4.  Respondent Concerns About Extended Cycle Product Use 
 
 
 
 
 
0 
5 
10 
15 
20 
25 
30 
35 
40 
45 
50 
P
e
rc
e
n
ta
ge
 o
f 
R
e
sp
o
n
d
e
n
ts
 C
o
n
ce
rn
e
d
  
Concerns of Extended Cycle Hormonal 
Contraceptive Regime 
Women taking Hormonal 
Contraceptives  
Women not taking Hormonal 
Contraceptives 
Figure 4 
